Long COVID Clinical Trial
Official title:
Digital Symptom Tracking and Wellness in Long COVID Patients Using Endourage Targeted Wellness Formula C™ Sublingual Drops
This is a digital symptom tracking study of Formula C™, a full cannabis flower formulation, rich in cannabinoids and terpenes, that has been shown to improve symptoms in people with Long COVID. Participants 21 and older will take Formula C™ for 90 days. During that time, participants will answer weekly surveys to track symptoms and wellbeing.
Long COVID is a global health crisis with no current treatments. There's a growing interest within the medical community to explore the potential benefits of full hemp flower extracts in treating and alleviating Long COVID symptoms. Full hemp flower extracts are a remarkable advancement in the field of natural wellness and healing. Full hemp flower extracts harness the full spectrum of beneficial compounds present in the hemp plant, including not just cannabidiol (CBD), but a host of other cannabinoids, terpenes, and flavonoids. This process, known as 'whole plant' or 'full spectrum' extraction, produces a more potent and therapeutic product, as the various compounds work synergistically in what is referred to as the 'entourage effect'. These extracts have been associated with a broad range of potential health benefits, such as pain relief, reduction of inflammation, anxiety management, and sleep improvement. A recently published single-blind, randomized, placebo controlled trial demonstrated that Long COVID patients benefitted from sublingual use of Formula C without any safety events. This remote, observational study of Endourage Targeted Wellness Formula C™ sublingual drops will seek to empower participants to track symptoms and wellbeing while taking Formula C to determine if Long COVID symptoms are attenuated and time to healing is shortened. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
| Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
| Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
| Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
| Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
| Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
| Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
| Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
| Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
| Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
| Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
| Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
| Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
| Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
| Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
| Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
| Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |